These changes in the tumor infiltrate resulted in the highest CD8/Treg ratio (Figure 4C), correlating with the best rate of anti-tumor efficacy observed in the group that received the triple combination GAd-62nag, anti-PD-1 and Ad-9D9. Here, CD8A is linked to neoplasm.